101 related articles for article (PubMed ID: 23990130)
1. Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
He X; Zhang T
Cell Biochem Biophys; 2014 Mar; 68(2):411-8. PubMed ID: 23990130
[TBL] [Abstract][Full Text] [Related]
2. Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Zhang YN; Wu XY; Zhong N; Deng J; Zhang L; Chen W; Li X; Zhong CJ
Mol Med Rep; 2014 Jan; 9(1):365-9. PubMed ID: 24213303
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
6. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
8. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
Mei J; Zhu X; Wang Z; Wang Z
Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
[TBL] [Abstract][Full Text] [Related]
11. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
12. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Rosetti M; Zoli W; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Granato AM; Amadori D; Silvestrini R
J Cell Physiol; 2007 Sep; 212(3):710-6. PubMed ID: 17458894
[TBL] [Abstract][Full Text] [Related]
13. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K
Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
[TBL] [Abstract][Full Text] [Related]
16. Ocimum sanctum induces apoptosis in A549 lung cancer cells and suppresses the in vivo growth of Lewis lung carcinoma cells.
Magesh V; Lee JC; Ahn KS; Lee HJ; Lee HJ; Lee EO; Shim BS; Jung HJ; Kim JS; Kim DK; Choi SH; Ahn KS; Kim SH
Phytother Res; 2009 Oct; 23(10):1385-91. PubMed ID: 19277950
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V
Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
20. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
